跳转至内容
Merck
CN

SML1575

Sigma-Aldrich

环孢菌素H

From Tolypocladium inflatum, ≥97% (HPLC), lentiviral transduction enhancer, powder

别名:

1,4,7,10,13,16,19,22,25,28,31-十一碳氮杂环三金刚烷,环肽衍生物, 5-(N-甲基-D-缬氨酸)-环孢菌素A

登录查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C62H111N11O12
化学文摘社编号:
分子量:
1202.61
UNSPSC代码:
51111800
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

环孢菌素H, ≥97% (HPLC)

生物来源

Tolypocladium inflatum

质量水平

方案

≥97% (HPLC)

表单

powder

旋光性

[α]/D -100 to -115°, c = 0.5 in methanol

储存条件

desiccated
protect from light

颜色

white to beige

储存温度

−20°C

SMILES字符串

N1([C@@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N(C(C(=O)N[C@H](C(=O)N(CC(=O)N([C@H](C1=O)CC(C)C)C)C)CC)[C@H](O)[C@@H](C\C=C\C)C)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)C

InChI

1S/C63H113N11O12/c1-26-28-29-41(15)53(76)52-56(79)66-44(27-2)58(81)67(18)34-49(75)68(19)46(31-36(5)6)60(83)72(23)50(39(11)12)62(85)69(20)45(30-35(3)4)55(78)64-42(16)54(77)65-43(17)57(80)70(21)47(32-37(7)8)59(82)71(22)48(33-38(9)10)61(84)73(24)51(40(13)14)63(86)74(52)25/h26,28,35-48,50-53,76H,27,29-34H2,1-25H3,(H,64,78)(H,65,77)(H,66,79)/b28-26+/t41-,42+,43-,44+,45+,46+,47+,48+,50-,51+,52?,53-/m1/s1

InChI key

BQQHPBPTWWXRMU-SXHXJWHLSA-N

应用

环孢素H已被用于:
  • 预培养用于转导的谱系缺失的小鼠 Flt3ITDIDH2R140Q BM 细胞
  • 作为甲酰肽受体(FPR)拮抗剂来研究FPR1在多形核白细胞(PMN)钙动员中的作用
  • 作为研究其对人类诱导多能干细胞(iPSC)和 T 细胞同源定向修复(HDR)编辑效率影响的小分子之一

生化/生理作用

环孢菌素 H 是中性粒细胞中甲酰肽受体 1(FPR-1)和甲酰肽诱导的超氧化物形成的选择性抑制剂。
环孢菌素 H 是中性粒细胞中甲酰肽受体 1(FPR-1)和甲酰肽诱导的超氧化物形成的选择性抑制剂。 环孢菌素 H 不结合亲环蛋白或引起免疫抑制反应。 据报道,环孢菌素 H 抑制小鼠皮肤细胞中促进肿瘤的佛波酯 TPA/PMA,并抑制钙/钙调蛋白依赖性的 EF-2 磷酸化。

象形图

Health hazardExclamation mark

警示用语:

Danger

危险声明

危险分类

Acute Tox. 4 Oral - Carc. 1B - Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Rana Gbyli et al.
Leukemia, 36(5), 1313-1323 (2022-03-12)
Treatment options for patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are scarce. Recurring mutations, such as mutations in isocitrate dehydrogenase-1 and -2 (IDH1/2) are found in subsets of AML and MDS, are therapeutically targeted by mutant
Ya-Wen Fu et al.
Nucleic acids research, 49(2), 969-985 (2021-01-06)
Investigations of CRISPR gene knockout editing profiles have contributed to enhanced precision of editing outcomes. However, for homology-directed repair (HDR) in particular, the editing dynamics and patterns in clinically relevant cells, such as human iPSCs and primary T cells, are
Woon Yong Kwon et al.
Proceedings of the National Academy of Sciences of the United States of America, 118(17) (2021-04-24)
Secondary infections typically worsen outcomes of patients recovering from septic shock. Neutrophil [polymorphonuclear leukocytes (PMNs)] migration to secondarily inoculated sites may play a key role in inhibiting progression from local bacterial inoculation to secondary infection. Mitochondrial N-formyl peptide (mtFP) occupancy
Giulia Rigotto et al.
Cells, 10(8) (2021-08-28)
In Alzheimer's disease (AD), the molecular mechanisms involved in the neurodegeneration are still incompletely defined, though this aspect is crucial for a better understanding of the malady and for devising effective therapies. Mitochondrial dysfunctions and altered Ca2+ signaling have long
Irene Sambri et al.
EBioMedicine, 61, 103050-103050 (2020-10-13)
Mutations of the mitochondrial protein paraplegin cause hereditary spastic paraplegia type 7 (SPG7), a so-far untreatable degenerative disease of the upper motoneuron with still undefined pathomechanism. The intermittent mitochondrial permeability transition pore (mPTP) opening, called flickering, is an essential process

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持